At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 11 enrolled
Drug / intervention
C21drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, 2-way Cross-over Trial Evaluating the Effect of C21 on Endothelial Dysfunction and Safety in Subjects With Type 2 Diabetes Mellitus
In Brief
A Phase 1 clinical trial evaluating C21 for Type2diabetes and Endothelial Dysfunction. Completed, enrolled 11 participants across 1 site.
Detailed Summary
This trial is a single-centre, randomized, double-blind, placebo-controlled, 2-way cross-over phase 1b trial evaluating the pharmacodynamic effect of C21 on endothelial dysfunction and safety in subjects with type 2 diabetes mellitus (T2DM).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType2diabetes, Endothelial Dysfunction
CountriesSweden
Collaborators--
Timeline
Phase 1CompletedFinished
202420252026
Enrollment StartMar 2023
First PostedApr 2023
Primary CompletionJun 2023
Study CompletionJun 2023
TodayJul 2026
First PostedApr 26, 2023
Enrollment StartMar 31, 2023
Primary CompletionJun 16, 2023
Study CompletionJun 20, 2023
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 3.2 years ago
Interventions
C21drug
C21 is an angiotensin II type 2 receptor agonist (ATRAG)